<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01624194</url>
  </required_header>
  <id_info>
    <org_study_id>SU-12132011-8827</org_study_id>
    <nct_id>NCT01624194</nct_id>
  </id_info>
  <brief_title>Intranasal Oxytocin Treatment for Social Deficits in Children With Autism</brief_title>
  <official_title>Double-blind, Randomized, Placebo Controlled Trial of Intranasal Oxytocin Treatment for Social Deficits in Children With Autism.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autism is a pervasive developmental disorder characterized by core deficits in social
      behavior and communication, and the presence of repetitive or stereotyped behaviors. It is
      one of three recognized disorders in the autism spectrum which affects an estimated 1 in 88
      children in the United States. At present, pharmacotherapies target only associated features
      of autism, with no effective drug treatments for the social impairments. Several lines of
      evidence now suggest that the neuropeptide oxytocin (OT) may be an effective treatment for
      the core social deficits in autism. Here we will test the effects of twice daily intranasal
      OT (24 IU) over a 4-week period for enhancing social deficits in male and female children
      aged 6-12 years with autism. This research has high potential to lead to the development of
      more effective treatments and earlier interventions for children with autism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In recent years, the neuropeptide oxytocin (OT) has been implicated in a wide range of social
      behaviors including attachment bonds, emotion recognition, eye gaze to social cues, and
      memory for social information. Social impairments represent one of the most intractable
      features of autism, and evidence now suggests that OT biology is dysregulated in individuals
      with this disorder. The central aim of the research outlined here is to test whether OT
      administration to children with autism increases their quality and quantity of social
      interactions and enhances their ability to process emotional and social information. Findings
      from initial single-dose OT administration studies in teenaged and adult males with autism
      have shown improvement in some aspects of social functioning, but replication and extension
      to well-controlled treatment trials with younger male and female subjects is necessary to
      evaluate effectiveness. We therefore aim to investigate the effect of intranasal OT on social
      cognition and behavior immediately following a single-dose (24IU) and following a 4-week
      period of OT (24IU BID) administration in a sample of 50 subjects with autism aged 6 to 12
      years. The primary outcome for this study is change in social behavior, as determined by
      parent ratings on the Social Responsiveness Scale (SRS) after the 4-week treatment period.
      Secondary outcomes are changes in functioning on laboratory-based measures of social behavior
      and cognition following single-dose and 4-week OT administration. Research in a small study
      sample (N=13) also identified treatment responders and non-responders to a single-dose of OT.
      Thus, we also aim to identify biological and cognitive and behavioral variables (i.e.,
      pretreatment levels of social functioning and pretreatment plasma hormone levels) that may
      influence treatment response efficacy in our larger study sample. On completion of the 4-week
      treatment period all subjects will have the option of participating in another 4-week
      double-blind trial in which they will be switched to the alternate nasal spray to that which
      they previously received. They will then undergo a fourth and final assessment time-point
      using the same testing procedures as outlined above on completion of the 4-week dosing. By
      providing subjects with the option of participating in a second 4-week treatment trial, all
      subjects will have an opportunity to receive the active oxytocin nasal spray. We also will be
      able to examine any ongoing effects of oxytocin treatment in the group receiving placebo
      during the second 4-week administration period. Subjects not willing to take part in the
      second trial will exit the study and will be referred to their treating physician.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2012</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Parent Rated Social Responsiveness Scale (SRS) Scores During Treatment.</measure>
    <time_frame>Baseline; Week 4</time_frame>
    <description>Social Responsiveness Scale (SRS) raw scores measure social abilities with lower raw scores meaning better social abilities. (Raw Score Range: 0 - 195)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Side Effects Assessed Using Parent Rated Dosage Record Treatment Emergent Symptom Scale (DOTES) Scores During Treatment</measure>
    <time_frame>Baseline through Week 4</time_frame>
    <description>Dosage Record Treatment Emergent Symptom Scale (DOTES) side effects reported by parents during 4-weeks of treatment. Participant Counts are used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Height.</measure>
    <time_frame>Baseline; Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-Improvement (CGI-I) Score at Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>This outcome is reported as the count of participants in each CGI-I rating category at the week 4 visit, assessing change over the 4-week period. CGI-I rating of 1=Very Much Improved, 2=Much Improved, 3=Minimally Improved, 4=No Change, 5=Minimally Worse, 6=Much Worse, and 7=Very Much Worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parent Rated Aberrant Behavior Checklist (ABC) Irritability Scores at Baseline and Week 4</measure>
    <time_frame>Baseline; Week 4</time_frame>
    <description>Higher scores indicate more symptoms, lower scores indicate fewer symptoms. Irritability scores can range from 0-45. Lethargy scores can range from 0-48. Stereotypy scores can range from 0-21. Hyperactivity scores can range from 0-48. Inappropriate speech scores can from 0-12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Parent Rated Spence Children's Anxiety Scale (SCAS) During Treatment.</measure>
    <time_frame>Baseline; Week 4</time_frame>
    <description>Scale measuring severity of anxiety symptoms. Higher scores mean higher levels of anxiety, lower scores mean lower levels of anxiety. (Raw Score Range: 0 - 114)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Vineland Adaptive Behavior Scales, Second Edition - Social and Communication Subscales During Treatment.</measure>
    <time_frame>Baseline; Week 4</time_frame>
    <description>Higher Social Standard Score means better social skills, lower Social Standard Score means worse social skills. Higher Communication Standard Score means better communication skills, lower Communication Standard Score means worse communication skills. Standard Scores can range from 20 to 160.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Laboratory Based Facial Emotion Recognition Abilities During Treatment.</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Laboratory Based Eye-gaze to Social Cues During Treatment.</measure>
    <time_frame>Baseline; Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Reading the Mind in the Eyes Test, Child Version (RMET-child) Scores During Treatment.</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Laboratory Based Social Mimicry Abilities During Treatment.</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Developmental NEuroPSYchological Assessment (NEPSY-II) Affect Recognition Scores During Treatment.</measure>
    <time_frame>Baseline; Week 4</time_frame>
    <description>Higher Affect Recognition scores mean better affect recognition abilities, lower Affect Recognition scores mean worse affect recognition abilities.
Scores can range from 1 to 19.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Oxytocin Levels During Treatment.</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>This outcome originally specified that oxytocin, vasopressin, and cortisol levels would be assessed; however, data on vasopressin and cortisol levels were not collected during the study.
There are no clinical laboratory tests that establish a normative range for oxytocin. Measurements prior to and following treatment were intended to evaluate oxytocin level as a predictor of response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Parent Rated Repetitive Behavior Scale- Revised (RBS-R) Scores During Treatment.</measure>
    <time_frame>Baseline; Week 4</time_frame>
    <description>Higher scores on the Repetitive Behavior Scale- Revised mean higher levels of repetitive and restricted behaviors. (Raw Score Total Range: 0 - 129)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Weight</measure>
    <time_frame>Baseline; Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Heart Rate</measure>
    <time_frame>Baseline; Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Pressure</measure>
    <time_frame>Baseline; Week 4</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Autism</condition>
  <arm_group>
    <arm_group_label>Oxytocin nasal spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prior to randomization, all subjects will participate in a 1-week open-label placebo lead-in trial. Each subject will be administered the placebo nasal spray at Stanford University and then their parent will continue administering the nasal spray to the subject for 1 week at home. Each subject will then be randomly assigned either to the active group or to the placebo (stratified by gender) and will be given the appropriate nasal spray bottle and their parents will be responsible for administering 3 puffs per nostril (4 IU/puff) to their child for a total dose of 24 IU oxytocin or placebo twice daily (BID; morning and evening) for 4-weeks. On completion of this 4-week treatment trial subjects will have the option of participating in a second double-blind trial in which they will be assigned to the alternate nasal spray, to that which they received during the first 4-week trial, for an additional 4-week period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo nasal spray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo nasal spray bottles will be prepared by adding all of the ingredients used in the Syntocinon nasal sprays with the exception of the concentrated oxytocin solution.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin nasal spray</intervention_name>
    <description>24IU BID (3 x 0.1 mL [4IU] sprays per nostril twice daily for 4-weeks.</description>
    <arm_group_label>Oxytocin nasal spray</arm_group_label>
    <other_name>Syntocinon® Nasal Spray</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>3 x 0.1 mL sprays per nostril twice daily for 4-weeks.</description>
    <arm_group_label>Placebo nasal spray</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Medically healthy outpatients between 6 and 12 years of age (cut off 12 years and 11
             months)

          -  Intelligence Quotient &gt; 40

          -  Diagnosis of autism spectrum disorder based on the Autism Diagnostic Interview -
             Revised, Autism Diagnostic Observation Schedule, and DSM-IV criteria

          -  Clinical Global Impression severity rating of 4 or higher

          -  Care provider who can reliably bring subject to clinic visits, provide trustworthy
             ratings, and interacts with the subject on a regular basis

          -  Stable medications for at least 4 weeks

          -  No planned changes in psychosocial interventions during the trial

          -  Willingness to provide blood samples.

        Exclusion Criteria:

          -  Diagnostics and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) diagnosis
             of schizophrenia, schizoaffective disorder, or psychotic disorder

          -  Regular nasal obstruction or nosebleeds

          -  Active medical problems: unstable seizures, significant physical illness (e.g.,
             serious liver, renal, or cardiac pathology)

          -  Sensitivity to preservatives (in particular E 216, E 218, and chlorobutanol
             hemihydrate)

          -  A genetic abnormality (e.g., Fragile X Syndrome)

          -  Significant hearing or vision impairments

          -  Habitually drinks large volumes of water

          -  Pregnancy, breastfeeding, or child birth within the last 6 months

          -  Sexually active females not using a reliable method of contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Y Hardan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karen J Parker, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Parker KJ, Oztan O, Libove RA, Sumiyoshi RD, Jackson LP, Karhson DS, Summers JE, Hinman KE, Motonaga KS, Phillips JM, Carson DS, Garner JP, Hardan AY. Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism. Proc Natl Acad Sci U S A. 2017 Jul 25;114(30):8119-8124. doi: 10.1073/pnas.1705521114. Epub 2017 Jul 10.</citation>
    <PMID>28696286</PMID>
  </results_reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 18, 2012</study_first_submitted>
  <study_first_submitted_qc>June 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2012</study_first_posted>
  <results_first_submitted>September 20, 2017</results_first_submitted>
  <results_first_submitted_qc>May 3, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 6, 2018</results_first_posted>
  <last_update_submitted>July 12, 2019</last_update_submitted>
  <last_update_submitted_qc>July 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Antonio Hardan</investigator_full_name>
    <investigator_title>Associate Professor of Child Psychiatry</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted in the Autism and Developmental Disabilities Clinic in the Division of Child and Adolescent Psychiatry at Stanford University. Recruitment began in June 2012 and ended in April 2016.
Participants were recruited through the Stanford Autism Research Registry, flyers posted in the community, posted online and special events.</recruitment_details>
      <pre_assignment_details>54 subjects were consented and assessed for eligibility. 19 subjects were excluded (13 did not meet inclusion criteria and 6 declined to participate). Additionally, 1 subject allocated to oxytocin did not receive allocated intervention due to parent declining to participate.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Oxytocin Nasal Spray</title>
          <description>Oxytocin nasal spray: 24IU twice daily (BID) (3 x 0.1 mL [4IU] sprays per nostril twice for 4-weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Nasal Spray</title>
          <description>Placebo: 3 x 0.1 mL sprays per nostril twice daily for 4-weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oxytocin Nasal Spray</title>
          <description>Oxytocin nasal spray: 24IU BID (3 x 0.1 mL [4IU] sprays per nostril twice for 4-weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Nasal Spray</title>
          <description>Placebo: 3 x 0.1 mL sprays per nostril twice daily for 4-weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Parent Rated Social Responsiveness Scale (SRS) Scores During Treatment.</title>
        <description>Social Responsiveness Scale (SRS) raw scores measure social abilities with lower raw scores meaning better social abilities. (Raw Score Range: 0 - 195)</description>
        <time_frame>Baseline; Week 4</time_frame>
        <population>Participants who completed the protocol are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin nasal spray: 24IU BID (3 x 0.1 mL [4IU] sprays per nostril twice for 4-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo: 3 x 0.1 mL sprays per nostril twice daily for 4-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Parent Rated Social Responsiveness Scale (SRS) Scores During Treatment.</title>
          <description>Social Responsiveness Scale (SRS) raw scores measure social abilities with lower raw scores meaning better social abilities. (Raw Score Range: 0 - 195)</description>
          <population>Participants who completed the protocol are included in the analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.73" spread="2.64"/>
                    <measurement group_id="O2" value="3.18" spread="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0275</p_value>
            <method>General Linear Model (GLM)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Side Effects Assessed Using Parent Rated Dosage Record Treatment Emergent Symptom Scale (DOTES) Scores During Treatment</title>
        <description>Dosage Record Treatment Emergent Symptom Scale (DOTES) side effects reported by parents during 4-weeks of treatment. Participant Counts are used.</description>
        <time_frame>Baseline through Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin nasal spray: 24IU BID (3 x 0.1 mL [4IU] sprays per nostril twice for 4-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo: 3 x 0.1 mL sprays per nostril twice daily for 4-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Side Effects Assessed Using Parent Rated Dosage Record Treatment Emergent Symptom Scale (DOTES) Scores During Treatment</title>
          <description>Dosage Record Treatment Emergent Symptom Scale (DOTES) side effects reported by parents during 4-weeks of treatment. Participant Counts are used.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cold Symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Excitement/Agitation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depressive Affect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Labile Mood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Silly Behavior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More Distractible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epistaxis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mouth Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intranasal Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blinking Eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Earache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loose Stool</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stomach Discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin Cut</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>Fisher's Exact Test was used to test for differences in adverse events between oxytocin-treated and placebo-treated individuals. A p-value of ≤0.05 would have been statistically significant.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Height.</title>
        <time_frame>Baseline; Week 4</time_frame>
        <population>Participants with available data are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin nasal spray: 24IU BID (3 x 0.1 mL [4IU] sprays per nostril twice for 4-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo: 3 x 0.1 mL sprays per nostril twice daily for 4-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Height.</title>
          <population>Participants with available data are included in the analysis.</population>
          <units>cm</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134" lower_limit="126" upper_limit="141"/>
                    <measurement group_id="O2" value="129" lower_limit="122" upper_limit="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134" lower_limit="127" upper_limit="142"/>
                    <measurement group_id="O2" value="129" lower_limit="122" upper_limit="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>A mixed-models analysis was used to compare between groups, and between baseline and Week 4.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression-Improvement (CGI-I) Score at Week 4</title>
        <description>This outcome is reported as the count of participants in each CGI-I rating category at the week 4 visit, assessing change over the 4-week period. CGI-I rating of 1=Very Much Improved, 2=Much Improved, 3=Minimally Improved, 4=No Change, 5=Minimally Worse, 6=Much Worse, and 7=Very Much Worse.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>Participants with available data are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin nasal spray: 24IU BID (3 x 0.1 mL [4IU] sprays per nostril twice for 4-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo: 3 x 0.1 mL sprays per nostril twice daily for 4-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression-Improvement (CGI-I) Score at Week 4</title>
          <description>This outcome is reported as the count of participants in each CGI-I rating category at the week 4 visit, assessing change over the 4-week period. CGI-I rating of 1=Very Much Improved, 2=Much Improved, 3=Minimally Improved, 4=No Change, 5=Minimally Worse, 6=Much Worse, and 7=Very Much Worse.</description>
          <population>Participants with available data are included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very Much Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Much Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parent Rated Aberrant Behavior Checklist (ABC) Irritability Scores at Baseline and Week 4</title>
        <description>Higher scores indicate more symptoms, lower scores indicate fewer symptoms. Irritability scores can range from 0-45. Lethargy scores can range from 0-48. Stereotypy scores can range from 0-21. Hyperactivity scores can range from 0-48. Inappropriate speech scores can from 0-12.</description>
        <time_frame>Baseline; Week 4</time_frame>
        <population>Participants with available data are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin nasal spray: 24IU BID (3 x 0.1 mL [4IU] sprays per nostril twice for 4-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo: 3 x 0.1 mL sprays per nostril twice daily for 4-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Parent Rated Aberrant Behavior Checklist (ABC) Irritability Scores at Baseline and Week 4</title>
          <description>Higher scores indicate more symptoms, lower scores indicate fewer symptoms. Irritability scores can range from 0-45. Lethargy scores can range from 0-48. Stereotypy scores can range from 0-21. Hyperactivity scores can range from 0-48. Inappropriate speech scores can from 0-12.</description>
          <population>Participants with available data are included.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Irritablity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.20" spread="11.91"/>
                    <measurement group_id="O2" value="13.94" spread="8.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.86" spread="8.87"/>
                    <measurement group_id="O2" value="11.78" spread="8.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Lethargy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.13" spread="8.70"/>
                    <measurement group_id="O2" value="11.7" spread="8.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 Lethargy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" spread="4.07"/>
                    <measurement group_id="O2" value="7.33" spread="6.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Stereotypy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.69" spread="6.20"/>
                    <measurement group_id="O2" value="5.61" spread="4.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 Stereotypy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.86" spread="5.07"/>
                    <measurement group_id="O2" value="5.50" spread="4.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Hyperactivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.00" spread="13.74"/>
                    <measurement group_id="O2" value="23.28" spread="10.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 Hyperactivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.50" spread="10.17"/>
                    <measurement group_id="O2" value="19.11" spread="9.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Inappropriate Speech</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.94" spread="3.28"/>
                    <measurement group_id="O2" value="5.44" spread="3.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 Inappropriate Speech</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.86" spread="3.23"/>
                    <measurement group_id="O2" value="4.17" spread="3.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Parent Rated Spence Children's Anxiety Scale (SCAS) During Treatment.</title>
        <description>Scale measuring severity of anxiety symptoms. Higher scores mean higher levels of anxiety, lower scores mean lower levels of anxiety. (Raw Score Range: 0 - 114)</description>
        <time_frame>Baseline; Week 4</time_frame>
        <population>Participants who completed the protocol are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin nasal spray: 24IU BID (3 x 0.1 mL [4IU] sprays per nostril twice for 4-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo: 3 x 0.1 mL sprays per nostril twice daily for 4-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Parent Rated Spence Children's Anxiety Scale (SCAS) During Treatment.</title>
          <description>Scale measuring severity of anxiety symptoms. Higher scores mean higher levels of anxiety, lower scores mean lower levels of anxiety. (Raw Score Range: 0 - 114)</description>
          <population>Participants who completed the protocol are included in the analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.66" spread="3.05"/>
                    <measurement group_id="O2" value="4.53" spread="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3395</p_value>
            <method>General Linear Model (GLM)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Vineland Adaptive Behavior Scales, Second Edition - Social and Communication Subscales During Treatment.</title>
        <description>Higher Social Standard Score means better social skills, lower Social Standard Score means worse social skills. Higher Communication Standard Score means better communication skills, lower Communication Standard Score means worse communication skills. Standard Scores can range from 20 to 160.</description>
        <time_frame>Baseline; Week 4</time_frame>
        <population>Participants with available data are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin nasal spray: 24IU BID (3 x 0.1 mL [4IU] sprays per nostril twice for 4-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo: 3 x 0.1 mL sprays per nostril twice daily for 4-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vineland Adaptive Behavior Scales, Second Edition - Social and Communication Subscales During Treatment.</title>
          <description>Higher Social Standard Score means better social skills, lower Social Standard Score means worse social skills. Higher Communication Standard Score means better communication skills, lower Communication Standard Score means worse communication skills. Standard Scores can range from 20 to 160.</description>
          <population>Participants with available data are included.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Social Standard Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.4" spread="12.82"/>
                    <measurement group_id="O2" value="67.75" spread="12.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 Social Standard Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.11" spread="16.03"/>
                    <measurement group_id="O2" value="70.92" spread="14.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Communication Standard Scores</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.91" spread="19.60"/>
                    <measurement group_id="O2" value="71.80" spread="17.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 Communication Standard Scores</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.33" spread="11.43"/>
                    <measurement group_id="O2" value="78.29" spread="19.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Laboratory Based Facial Emotion Recognition Abilities During Treatment.</title>
        <time_frame>Up to 4 weeks</time_frame>
        <population>Data were not collected for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin nasal spray: 24IU BID (3 x 0.1 mL [4IU] sprays per nostril twice for 4-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo: 3 x 0.1 mL sprays per nostril twice daily for 4-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Laboratory Based Facial Emotion Recognition Abilities During Treatment.</title>
          <population>Data were not collected for this outcome.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Laboratory Based Eye-gaze to Social Cues During Treatment.</title>
        <time_frame>Baseline; Week 4</time_frame>
        <population>Data not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin nasal spray: 24IU BID (3 x 0.1 mL [4IU] sprays per nostril twice for 4-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo: 3 x 0.1 mL sprays per nostril twice daily for 4-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Laboratory Based Eye-gaze to Social Cues During Treatment.</title>
          <population>Data not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Reading the Mind in the Eyes Test, Child Version (RMET-child) Scores During Treatment.</title>
        <time_frame>Up to 4 weeks</time_frame>
        <population>Data were not not collected for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin nasal spray: 24IU BID (3 x 0.1 mL [4IU] sprays per nostril twice for 4-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo: 3 x 0.1 mL sprays per nostril twice daily for 4-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Reading the Mind in the Eyes Test, Child Version (RMET-child) Scores During Treatment.</title>
          <population>Data were not not collected for this outcome.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Laboratory Based Social Mimicry Abilities During Treatment.</title>
        <time_frame>Up to 4 weeks</time_frame>
        <population>Data were not not collected for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin nasal spray: 24IU BID (3 x 0.1 mL [4IU] sprays per nostril twice</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo: 3 x 0.1 mL sprays per nostril twice daily for 4-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Laboratory Based Social Mimicry Abilities During Treatment.</title>
          <population>Data were not not collected for this outcome.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Developmental NEuroPSYchological Assessment (NEPSY-II) Affect Recognition Scores During Treatment.</title>
        <description>Higher Affect Recognition scores mean better affect recognition abilities, lower Affect Recognition scores mean worse affect recognition abilities.
Scores can range from 1 to 19.</description>
        <time_frame>Baseline; Week 4</time_frame>
        <population>Participants with available data were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin nasal spray: 24IU BID (3 x 0.1 mL [4IU] sprays per nostril twice for 4-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo: 3 x 0.1 mL sprays per nostril twice daily for 4-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Developmental NEuroPSYchological Assessment (NEPSY-II) Affect Recognition Scores During Treatment.</title>
          <description>Higher Affect Recognition scores mean better affect recognition abilities, lower Affect Recognition scores mean worse affect recognition abilities.
Scores can range from 1 to 19.</description>
          <population>Participants with available data were included.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Affect Recognition Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" spread="1.89"/>
                    <measurement group_id="O2" value="9.43" spread="3.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 Affect Recognition Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.75" spread="1.5"/>
                    <measurement group_id="O2" value="6.43" spread="4.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Oxytocin Levels During Treatment.</title>
        <description>This outcome originally specified that oxytocin, vasopressin, and cortisol levels would be assessed; however, data on vasopressin and cortisol levels were not collected during the study.
There are no clinical laboratory tests that establish a normative range for oxytocin. Measurements prior to and following treatment were intended to evaluate oxytocin level as a predictor of response.</description>
        <time_frame>Up to 4 weeks</time_frame>
        <population>Participants with available data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin nasal spray: 24IU BID (3 x 0.1 mL [4IU] sprays per nostril twice for 4-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo: 3 x 0.1 mL sprays per nostril twice daily for 4-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Oxytocin Levels During Treatment.</title>
          <description>This outcome originally specified that oxytocin, vasopressin, and cortisol levels would be assessed; however, data on vasopressin and cortisol levels were not collected during the study.
There are no clinical laboratory tests that establish a normative range for oxytocin. Measurements prior to and following treatment were intended to evaluate oxytocin level as a predictor of response.</description>
          <population>Participants with available data were included in the analysis.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.82" spread="4.67"/>
                    <measurement group_id="O2" value="8.66" spread="3.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.36" spread="3.57"/>
                    <measurement group_id="O2" value="8.40" spread="3.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Parent Rated Repetitive Behavior Scale- Revised (RBS-R) Scores During Treatment.</title>
        <description>Higher scores on the Repetitive Behavior Scale- Revised mean higher levels of repetitive and restricted behaviors. (Raw Score Total Range: 0 - 129)</description>
        <time_frame>Baseline; Week 4</time_frame>
        <population>Only analyzed after 4 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin nasal spray: 24IU BID (3 x 0.1 mL [4IU] sprays per nostril twice for 4-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo: 3 x 0.1 mL sprays per nostril twice daily for 4-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Parent Rated Repetitive Behavior Scale- Revised (RBS-R) Scores During Treatment.</title>
          <description>Higher scores on the Repetitive Behavior Scale- Revised mean higher levels of repetitive and restricted behaviors. (Raw Score Total Range: 0 - 129)</description>
          <population>Only analyzed after 4 weeks.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.68" spread="3.32"/>
                    <measurement group_id="O2" value="5.79" spread="2.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.9757</p_value>
            <method>General Linear Model (GLM)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Weight</title>
        <time_frame>Baseline; Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin nasal spray: 24IU BID (3 x 0.1 mL [4IU] sprays per nostril twice for 4-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo: 3 x 0.1 mL sprays per nostril twice daily for 4-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weight</title>
          <units>kilograms</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.7" lower_limit="27.0" upper_limit="39.5"/>
                    <measurement group_id="O2" value="28.0" lower_limit="23.5" upper_limit="33.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5" lower_limit="27.7" upper_limit="40.4"/>
                    <measurement group_id="O2" value="28.4" lower_limit="23.9" upper_limit="33.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>A mixed-models analysis was used to compare between groups, and between baseline and Week 4.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Heart Rate</title>
        <time_frame>Baseline; Week 4</time_frame>
        <population>Participants with available data are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin nasal spray: 24IU BID (3 x 0.1 mL [4IU] sprays per nostril twice for 4-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo: 3 x 0.1 mL sprays per nostril twice daily for 4-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Heart Rate</title>
          <population>Participants with available data are included in the analysis.</population>
          <units>beats per minute</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Sitting Heart Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.5" lower_limit="83.0" upper_limit="101.9"/>
                    <measurement group_id="O2" value="92.7" lower_limit="83.6" upper_limit="101.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post 4 -Week Sitting Heart Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.1" lower_limit="87.7" upper_limit="106.5"/>
                    <measurement group_id="O2" value="101.6" lower_limit="92.5" upper_limit="110.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Blood Pressure</title>
        <time_frame>Baseline; Week 4</time_frame>
        <population>Participants with available data are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Nasal Spray</title>
            <description>Oxytocin nasal spray: 24IU BID (3 x 0.1 mL [4IU] sprays per nostril twice for 4-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Nasal Spray</title>
            <description>Placebo: 3 x 0.1 mL sprays per nostril twice daily for 4-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Pressure</title>
          <population>Participants with available data are included in the analysis.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Systolic Blood Pressure, Sitting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.2" lower_limit="98.7" upper_limit="109.8"/>
                    <measurement group_id="O2" value="101.0" lower_limit="95.6" upper_limit="106.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post 4 -Week Systolic Blood Pressure, Sitting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.1" lower_limit="105.5" upper_limit="116.6"/>
                    <measurement group_id="O2" value="110.9" lower_limit="105.6" upper_limit="116.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Diastolic Blood Pressure, Sitting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.3" lower_limit="59.0" upper_limit="69.6"/>
                    <measurement group_id="O2" value="64.6" lower_limit="59.4" upper_limit="69.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post 4 -Week Diastolic Blood Pressure, Sitting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4" lower_limit="66.1" upper_limit="76.7"/>
                    <measurement group_id="O2" value="68.9" lower_limit="63.8" upper_limit="74.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Systolic Blood Pressure, Standing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.6" lower_limit="95.2" upper_limit="108.1"/>
                    <measurement group_id="O2" value="107.7" lower_limit="101.5" upper_limit="113.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post 4 -Week Systolic Blood Pressure, Standing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.6" lower_limit="105.2" upper_limit="118.1"/>
                    <measurement group_id="O2" value="105.6" lower_limit="99.4" upper_limit="111.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Diastolic Blood Pressure, Standing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.3" lower_limit="58.0" upper_limit="68.6"/>
                    <measurement group_id="O2" value="68.2" lower_limit="63.1" upper_limit="73.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post 4 -Week Diastolic Blood Pressure, Standing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.9" lower_limit="65.6" upper_limit="76.2"/>
                    <measurement group_id="O2" value="69.8" lower_limit="64.7" upper_limit="74.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>For all blood pressure analyses.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Oxytocin Nasal Spray</title>
          <description>Oxytocin nasal spray: 24IU BID (3 x 0.1 mL [4IU] sprays per nostril twice for 4-weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Nasal Spray</title>
          <description>Placebo: 3 x 0.1 mL sprays per nostril twice daily for 4-weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Earache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blinking Eyes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Loose Stool</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Stomach Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cold Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Mouth Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Intranasal Swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Runny Nose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nasal Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Excitement/Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Depressive Affect</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Labile Mood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Silly Behavior</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>More Distractible</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Cut</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The final sample was 84% male and was not powered to detect sex differences in treatment response. Participants were permitted to take other medications during the intervention. Many of our outcome measures relied on parent report.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Antonio Y. Hardan, MD</name_or_title>
      <organization>Stanford University</organization>
      <phone>(650) 736-1235</phone>
      <email>hardanay@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

